In a recent trials, doctors have found that Abatacept works well in patients with early and erosive rheumatoid arthritis and also in subjects with established disease.
Abatacept (Orencia) is an injectable synthetic protein produced by recombinant DNA technology, used for the treatment of rheumatoid arthritis.In the past, significant advances in the understanding of Rheumatoid Arthritis (RA) and its management have been made, resulting in intervention with biologic Disease-Modifying Anti-rheumatic Drugs (DMARDs) in patients with evidence of aggressive and erosive disease.
Dr. Michael Schiff and his colleagues from School of Medicine, University of Colorado and worked on a biologic therapy, the T-cell co-stimulation modulator Abatacept. They went on to explore the clinical evidences published till date on its use in subjects with early arthritis/ RA who are Methotrexate MTX () and in patients with established RA with an inadequate response to MTX.
The clinical data from 10, 366 patient was analysed. The drug was found to be relatively safe. In some patients serious infections, autoimmune events and malignancies was noted. The authors concluded the study by confirming that Abatacept proves to be an effective treatment option among different patient populations, including subjects with early and erosive RA and those with established disease.
Additionally, efficacy data in patients with early disease indicate that the risk-benefit profile of Abatacept may be more favorable if and when introduced earlier in the treatment model. Reference